| 3.59 0.03 (0.84%) | 05-22 12:35 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.84 | 1-year : | 0.98 |
| Resists | First : | 0.72 | Second : | 0.84 |
| Pivot price | 0 | |||
| Supports | First : | 0.66 | Second : | 0.62 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 0.72 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MYNZ ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.
Fri, 13 Mar 2026
Mainz Biomed changes ticker symbol to QUCY - MSN
Tue, 02 Sep 2025
Mainz Biomed (MYNZ) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Mon, 19 May 2025
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com
Tue, 08 Aug 2023
Mainz Biomed B.V. (MYNZ) Dividend History, Date, and Yield - CoinCodex
Wed, 05 Apr 2023
Mainz Biomed B.V. (MYNZ) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Wed, 05 Apr 2023
Mainz Biomed B.V. (MYNZ) Stock Live Price, Chart & News - CoinCodex
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|